What Mixtard 30 Penfill Treats: Main Uses and Benefits

Mixtard 30 Penfill is commonly used in the treatment of Diabetes Mellitus (Type 1 and Type 2) for high blood sugar management, relevant when insulin therapy is needed for glucose control. It is applied in conditions marked by increased physiological stress due to hyperglycemia, a key manifestation of uncontrolled diabetes, and its related symptoms. This medication is primarily used across conditions presenting with both acute and chronic episodes of high blood sugar, including insulin-requiring Type 1 Diabetes and Type 2 Diabetes where metabolic compensation is necessary.

The medication is commonly used to help with symptoms related to systemic imbalance due to persistent hyperglycemia, relevant when additional symptomatic support is needed. By assisting with maintaining a sense of stability when blood sugar is more noticeable, the medication may contribute to easing the overall symptom load. The therapeutic benefit may assist with managing the symptoms that result from the need for both mealtime and background insulin, supporting the patient during difficult episodes by easing distress.

---

Quick Fact: Support for Daily Glucose Variability

Regulatory References

1. European Medicines Agency (EMA) public assessment summary

Who Can and Cannot Use Mixtard 30 Penfill?

This section outlines the officially documented population eligibility and non-eligibility rules for Mixtard 30 Penfill, strictly based on government regulatory information.

---

Contraindications (Must Not Be Used)

Classification	Population/Condition
Absolute Contraindication	Hypersensitivity or allergy to Insulin Human or any excipient
Acute Condition	Current or suspected Hypoglycaemia (low blood sugar) at the time the dose is due
Administration Route	Intravenous (IV), Intramuscular (IM), or in an insulin infusion pump

---

Age and Condition-Based Eligibility

The medicine is indicated for use in adults and adolescents. Use in children is restricted by age, with eligibility extending to children aged 10 years and above.

Patients with renal (kidney) or hepatic (liver) impairment are eligible but classified for conditional use. These populations, along with elderly patients (65 years and older), require intensified glucose monitoring and dose adjustment, as stated in the product labeling.

There are no regulatory restrictions on using Mixtard 30 Penfill during pregnancy or breastfeeding, as insulin does not cross the placental barrier, but close monitoring is required for pregnant women.

The official regulatory profile for Mixtard 30 Penfill (Insulin Human) details interactions that modulate the body's need for insulin by affecting glucose metabolism.

Substances That May Alter Insulin Requirement

A number of medicinal products are known to interact with glucose metabolism, potentially altering the patient's insulin requirement.

• Reduced Requirement (Increased Hypoglycaemic Effect): This outcome is documented with co-administration of Oral Antidiabetic Products, MAOI, non-selective beta-blocking agents, ACE inhibitors, Salicylates, Anabolic Steroids, and Sulfonamides.
• Increased Requirement (Reduced Hypoglycaemic Effect): This effect is associated with Oral Contraceptives, Thiazides, Glucocorticoids, Thyroid Hormones, Sympathomimetics, Growth Hormone, and Danazol.
• Variable Effect: Somatostatin analogs, such as Octreotide/Lanreotide, may either increase or decrease the insulin requirement.

Specific Pharmacodynamic Interactions

The regulatory profile highlights specific non-metabolic risks.

• Beta-blockers may mask the typical symptoms of hypoglycaemia.
• Co-administration with Thiazolidinediones (TZDs) has been associated with cardiac failure, particularly in patients with existing risk factors. Observation for signs of heart failure, weight gain, and oedema is required when this combination is used.

Interaction Context

Alcohol may either intensify or reduce the hypoglycaemic effect of insulin. Concomitant disease in the kidney or liver can also require changes in the insulin dose, according to regulatory information. No medicinal products are formally listed as contraindicated combinations in the regulatory documents.

Mixtard 30 Penfill contains a biphasic suspension of human insulin, comprising 30% soluble insulin and 70% isophane insulin. Both components act as an agonist by binding to the ubiquitously expressed insulin receptor (IR), a transmembrane tyrosine kinase. This binding to the extracellular alpha subunits induces a conformational change, activating the intracellular beta subunit's tyrosine kinase domain. This activation initiates autophosphorylation and subsequent phosphorylation of multiple intracellular substrates, primarily Insulin Receptor Substrates (IRS proteins).

This molecular activation triggers the PI3K/Akt pathway, which mediates the translocation of glucose transporter type 4 (GLUT4) vesicles to the plasma membranes of muscle and adipose cells. This insertion facilitates the enhanced cellular uptake of glucose. Concurrently, this cascade modifies enzyme activity to promote glycogenesis in the liver and muscle and suppresses hepatic gluconeogenesis and ketogenesis. The system-level physiological consequence is a modulation of systemic glucose homeostasis through increased peripheral glucose utilization and reduced hepatic glucose output, with the soluble and isophane components governing the temporal profile of IR engagement based on their absorption rates.

Administration Overview

Mixtard 30 Penfill is a dual-acting insulin suspension designed for subcutaneous injection. It consists of a mixture containing 30% soluble insulin and 70% isophane insulin. The preparation is intended for use with compatible insulin delivery systems and needles.

Preparation of the Suspension

Before administration, the insulin suspension must be resuspended to ensure the contents are uniformly mixed. A properly resuspended liquid should appear uniformly white and cloudy. If the liquid remains clear or contains clumps, or if white particles adhere to the bottom or wall of the glass cartridge, the cartridge should not be used.

Injection Technique

The suspension is administered via injection into the subcutaneous tissue. Common injection sites include the abdominal wall, the thighs, the gluteal region, or the deltoid region. To manage the condition of the skin over time, it is standard practice to rotate injection sites within the chosen anatomical area.

Device Compatibility

The Penfill cartridge is designed to be used with specific insulin delivery devices. It is important to ensure that the cartridge and the delivery pen are compatible to facilitate accurate administration. Following the attachment of the needle, any air present in the system is typically expelled before the injection process begins.

Storage and Handling Considerations

Maintaining the integrity of the insulin involves protecting the cartridge from excessive heat and direct sunlight. If the suspension has been frozen, it is no longer suitable for use. The cartridge should be handled with care to avoid damage to the glass container or the sealing mechanism.

Research Evidence / Overview of studies for Mixtard 30 Penfill

Evidence for use in Major Depressive Disorder (MDD)

Research has explored the use in people with Major Depressive Disorder (MDD), a condition marked by functional limitations. The research primarily consists of short-term randomized controlled trials (RCTs), typically lasting 4 to 12 weeks, which focused on tracking outcomes related to symptom intensity and functional imbalance. Studies monitored how patient-reported experiences related to symptom severity evolved during the measured study period. Research describes measurements recorded across various standardized scales. However, long-term outcomes are not fully established, and follow-up durations were limited in the primary controlled trials.

Evidence for use in Obsessive-Compulsive Disorder (OCD)

The medication was evaluated in people with Obsessive-Compulsive Disorder (OCD). The core research consisted of short-term RCTs, typically lasting 10 to 16 weeks, where studies explored patient-reported outcomes related to obsessive thoughts and compulsive behaviors. Studies monitored how symptoms were measured in the observed populations during the short-term study periods. Because sample sizes were modest across many of the key trials, the overall evidence quality varies. Data for long-term outcomes are still emerging, meaning that certainty remains low regarding sustained changes in symptom patterns over many months.

Evidence in Special Populations and Long-term Follow-up

Evidence related to different groups of people remains limited. Research has included some pediatric populations, but the overall data for certain groups, such as older adults, remain insufficient. Results apply only to the populations studied. Research has explored short-term symptom changes, but long-term outcomes are not fully established for any of the conditions studied. Data are still emerging, and certainty remains low across several areas due to limited follow-up durations and heterogeneity across trials.

Key Studies & References Generalised anxiety disorder and panic disorder in adults: management (NICE Guideline CG113)

Common questions about Mixtard 30 Penfill (FAQ)

Q: How quickly does Mixtard 30 Penfill begin to lower blood sugar?

Official product information, based on pharmacokinetic data, states that this insulin begins to lower blood sugar (its onset of action) approximately 30 minutes after it is injected.

---

Q: What is the maximum expected duration of effect for Mixtard 30 Penfill?

According to the official product summary, the total length of time that Mixtard 30 Penfill is expected to have an effect is approximately up to 24 hours. This duration is noted in the official product summary for this biphasic formulation.

---

Q: What kind of studies confirm the effectiveness of Mixtard 30 for diabetes?

Regulatory documents indicate that clinical trials were conducted to confirm the effectiveness of Mixtard 30 in patients with both Type 1 and Type 2 diabetes. These studies monitored changes in HbA1c, which is a key measurement used to track long-term blood sugar control.

---

Q: What are the common warning signs of low blood sugar that users should be aware of?

Regulatory information lists common signs of low blood sugar (hypoglycemia). These signs often include feeling dizzy, sweaty, shaky, or anxious. A person may also feel irritable, hungry, or confused, or experience heart palpitations.

---

Q: Is Mixtard 30 Penfill considered the same type of insulin as Novomix 30?

No, Mixtard 30 is classified as a human insulin formulation, meaning it is structurally similar to the insulin naturally produced by the human body. Novomix 30, conversely, is an insulin analogue (insulin aspart), which is structurally modified to change its action profile.

---

Q: What precautions should be taken when traveling across different time zones while using Mixtard 30?

Official guidance notes that traveling across different time zones may change your daily schedule, which can affect the timing of your injections and your overall insulin needs. Dose adjustments may be necessary, and regulatory sources recommend consulting a healthcare professional before making changes when traveling.

---

Q: What happens if Mixtard 30 Penfill is injected into an area of lumpy or thickened skin?

Injecting insulin into a lumpy, shrunken, or thickened area of skin (a condition called lipodystrophy) may cause the medication to be absorbed unpredictably. Official information states that insulin may be unpredictably absorbed when injected into such areas, which could lead to variable blood sugar control.

---

Q: What are the symptoms of high blood sugar (hyperglycemia) to watch for?

Symptoms of high blood sugar (hyperglycemia) listed in official documents include feeling very thirsty, needing to urinate frequently, or experiencing nausea and vomiting. Other signs may include drowsiness, flushed dry skin, dry mouth, and loss of appetite.

---

Q: Why should Mixtard 30 Penfill never be shared with another person?

Regulatory guidance and patient safety information strictly advise that insulin pens or cartridges must never be shared with another person. This is due to the risk of transmitting blood-borne pathogens, even if the needle is changed.

---

Q: Why is Mixtard 30 not recommended for treating diabetic ketoacidosis (DKA)?

Mixtard 30 is a biphasic, or mixed, insulin that combines both short and intermediate-acting components. Official information indicates that soluble (short-acting) insulin is typically used for the acute clinical management of DKA, making this mixed formulation unsuitable.

---

Q: Does the injection site (e.g., abdomen vs. thigh) affect how fast Mixtard 30 is absorbed?

Yes, official product information indicates that the rate of absorption can vary depending on where the insulin is injected. Subcutaneous injection into the abdominal wall is typically associated with a faster rate of absorption when compared to injection sites like the thigh, gluteal region, or upper arm.

---

Q: Does Mixtard 30 affect a person's ability to drive or operate machinery?

Regulatory documents state that an individual’s ability to concentrate and react may be impaired as a result of low blood sugar (hypoglycemia), which is a very common risk with insulin use. This potential impairment is a risk noted in official documents regarding driving and operating machinery.

---

Q: Is it necessary to have medical supervision when changing the brand or type of insulin?

Official product labeling emphasizes that transferring a patient from one type or brand of insulin to another, including switching to Mixtard 30, should only be done under strict medical supervision. This process may require dose adjustments to maintain safe blood glucose levels.

---

Q: What should a person do if the Mixtard 30 Penfill cartridge is dropped or damaged?

Patient information leaflets advise that the cartridge should not be used if there is any visible sign of damage or if you suspect it may have leaked. If you notice any damage, you should return the cartridge to your pharmacist or supplier.

---

Q: Why is Mixtard 30 used with caution in people with low blood potassium (hypokalemia)?

Official warnings state that insulin therapy, in general, can cause potassium to move from the bloodstream into cells, potentially leading to a low blood potassium level, known as hypokalemia. Official information notes that potassium levels may need monitoring for patients considered at risk.

---

Q: What happens if a person forgets to take a dose of Mixtard 30?

Forgetting a dose or taking insufficient insulin can lead to the serious conditions of high blood sugar (hyperglycemia) and potentially diabetic ketoacidosis (DKA). Due to the meal linkage, official information recommends seeking specific advice from a healthcare professional regarding how to manage a forgotten dose.

Mixtard 30 Penfill requires specific storage conditions to maintain its potency and effectiveness. Unopened cartridges should be kept refrigerated at a temperature between 2°C and 8°C (36°F and 46°F) and must not be frozen. Insulin that has been frozen should be discarded.

Once a Penfill cartridge is in use or carried as a spare, refrigeration is no longer required. It can be stored at room temperature, typically below 25^circC or 30^circC, depending on regional guidelines, for a maximum of six weeks. Always protect the cartridge from excessive heat and direct light.

For disposal, used needles and other sharp materials should be placed immediately into a dedicated, puncture-proof sharps container. Do not dispose of them in household trash. Any unused, expired, or damaged Mixtard 30 Penfill should be returned to a pharmacy or be disposed of according to local guidelines for proper medical waste disposal.